How Do the S&P 500's Other 493 Stocks Perform Without the Magnificent 7?

What Is the S&P 500 Ex-Magnificent 7 and How Is It Calculated?

The S&P 500 ex-Magnificent 7 is not an official index product from S&P Dow Jones Indices. It is an analytical construct: the performance of the S&P 500's 493 remaining constituents after removing Apple, Microsoft, Alphabet, Amazon, NVIDIA, Meta Platforms, and Tesla. You calculate it by stripping those seven positions from the cap-weighted index and re-examining what the other 493 companies are actually doing.

Why does this matter now? As of Q4 2024, the Magnificent Seven collectively represented approximately 31 to 33% of the S&P 500's total market capitalization. That concentration level has not been seen since the Nifty Fifty era of the early 1970s. For a FatFIRE investor running a standard 60/40 allocation on a $5M portfolio, that translates to roughly $1M of effective single-sector concentration risk sitting inside what most people assume is a diversified index fund.

The S&P 500 Equal Weight Index (ticker: RSP), which S&P Dow Jones Indices assigns a fixed 0.2% weight to each constituent at every quarterly rebalance, is the closest publicly available proxy for an ex-concentration view of the market. It is not identical to an ex-Mag 7 construct, but it removes the distortion that seven stocks create when they collectively outweigh the bottom 200 names combined.

Understanding market performance beyond the Magnificent 7 starts with accepting that the headline S&P 500 number you see quoted daily is, at this point, largely a report on seven companies.

How Has the S&P 500 Ex-Magnificent 7 Performed Compared to the Full Index?

The performance gap is real, and the direction has flipped depending on the time window you choose.

Over full market cycles spanning 20-plus years, the S&P 500 Equal Weight Index has historically outperformed the cap-weighted index. Broader participation, mean reversion in valuations, and the compounding effect of not being overweight whatever the current consensus darling is have all contributed to that long-run edge.

The 2023 to 2024 period told a different story. Magnificent Seven earnings growth diverged sharply from the rest of the index, and the cap-weighted S&P 500 significantly outpaced equal-weight and ex-concentration alternatives. That divergence is precisely what created the valuation gap that now exists.

As of late 2024, Morningstar's market valuation data shows the median P/E ratio for S&P 500 companies outside the largest ten holdings trading at a meaningful discount to the index's headline P/E, which is heavily skewed by mega-cap tech multiples. The forward P/E of the S&P 500 ex-Mag 7 universe ran approximately 17 to 18x versus 25 to 28x for the Magnificent Seven. Historically, spreads of that magnitude have reverted.

For context on ten-year historical performance analysis and five-year market trends and performance, the pattern is consistent: concentration in a small number of mega-cap firms has historically been associated with elevated valuation dispersion between the largest and median constituents, creating mean-reversion opportunities in the broader market, according to research from the Federal Reserve Bank of San Francisco.

The Vanguard 2025 Economic and Market Outlook projects that U.S. large-cap equities face compressed 10-year forward returns relative to international and value-oriented segments, partly due to elevated concentration and valuation premiums in mega-cap technology. That is not a call to exit the Mag 7. It is a call to know what you actually own.

What Sectors Make Up the S&P 500 Excluding the Magnificent Seven?

Strip out the seven, and the sector composition shifts materially. The ex-Mag 7 universe looks much closer to a value and dividend blend than a growth index. Financials, healthcare, industrials, and consumer staples collectively represent a much larger share of the ex-Mag 7 universe than they do in the headline index.

The S&P 500 sector classifications cover eleven distinct groups, and how sector weights have shifted over time tells the story of technology's growing dominance. Here is how the composition compares once you remove the seven largest names:

The financial sector opportunities and the healthcare weighting are the two most consequential shifts. Financials are more sensitive to interest rate movements and credit cycles. Healthcare carries regulatory risk but also provides genuine defensive characteristics during equity drawdowns.

The technology sector's weight in the index makes clear how much the headline number obscures: even after removing the Magnificent Seven, information technology still represents roughly 10 to 11% of the ex-Mag 7 universe. The sector does not disappear. It just stops being the only thing that matters.

Is the S&P 500 Ex-Magnificent 7 Overvalued or Undervalued Compared to Mega-Cap Tech?

At late 2024 valuations, the ex-Mag 7 universe looks cheap relative to its own history and dramatically cheap relative to the Magnificent Seven. Whether that discount is justified or represents an opportunity depends on your view of earnings sustainability.

The NBER research by De Loecker, Eeckhout, and Unger documents that aggregate corporate markups in the U.S. have risen substantially since 1980, concentrated disproportionately among the largest firms. That helps explain the persistent earnings premium that mega-cap technology commands. The Magnificent Seven are not overvalued purely because they are large. They are expensive because the market is pricing in continued dominance of their competitive moats.

The counterargument is reversion. A 17 to 18x forward P/E on the ex-Mag 7 universe, against a backdrop of solid earnings growth in financials and healthcare, is not a distressed valuation. It is simply unloved. Research published in the Journal of Financial Planning finds that portfolios with more than 25 to 30% concentration in a single sector or correlated group of stocks exhibit materially higher drawdown risk without commensurate improvement in risk-adjusted returns over full market cycles.

The S&P 500 quality index provides another lens here. Quality factor screens, which emphasize return on equity, earnings stability, and low financial leverage, tend to surface companies in financials, healthcare, and industrials at attractive valuations relative to the mega-cap growth cohort.

The honest answer: the ex-Mag 7 universe is not obviously undervalued in absolute terms. It is undervalued relative to the Magnificent Seven by a spread that has historically not persisted indefinitely. That is a probabilistic argument, not a guarantee.

Sector Performance Across the Broader Market: What the Data Shows

Sector performance across the broader market in 2023 and 2024 illustrated a bifurcated economy. The Magnificent Seven's AI-driven earnings growth pulled the headline index higher while many ex-Mag 7 sectors delivered flat to modest returns.

Financials benefited from higher-for-longer interest rates through net interest margin expansion, particularly at regional banks that survived the 2023 stress period. Healthcare underperformed expectations as GLP-1 drug enthusiasm concentrated gains in a handful of names (Eli Lilly, Novo Nordisk) while the broader sector lagged. Industrials held up reasonably well on infrastructure spending and reshoring themes. Energy was volatile, tracking oil prices more than any fundamental re-rating.

The dividend yield differential is tangible for investors in or near the distribution phase. The S&P 500 ex-Mag 7 dividend yield running approximately 1.8 to 2.2% versus under 1.3% for the full cap-weighted index is not a trivial difference on a $5M equity allocation. That gap represents $25,000 to $45,000 in additional annual income before any price appreciation.

Utilities and consumer staples, the two most defensive ex-Mag 7 sectors, underperformed sharply in the rising rate environment of 2022 to 2023 as their bond-proxy characteristics became liabilities. With rates potentially stabilizing, those sectors warrant a second look for income-focused portfolios.

Should High-Net-Worth Investors Reduce Concentration Risk from Magnificent Seven Holdings?

This is the question your financial advisor may be dancing around. Here is the direct version.

If you have been accumulating a standard S&P 500 index fund for the past decade, you have roughly one-third of your U.S. equity exposure in seven stocks. On a $3M equity allocation within a $5M portfolio, that is approximately $1M concentrated in a correlated group of high-multiple technology companies. Most investors do not think of their S&P 500 index fund as a concentrated tech bet. It is.

The concentration argument is not that the Magnificent Seven are bad businesses. They are exceptional businesses. The argument is that exceptional businesses at 25 to 28x forward earnings, representing a third of the index, create asymmetric downside risk if sentiment shifts, regulation tightens, or AI monetization timelines disappoint.

S&P 500 versus total market strategies and S&P 500 compared to the Nasdaq 100 both illustrate how different the risk profile looks when you adjust for concentration. The Nasdaq 100 makes the concentration problem explicit. The S&P 500 obscures it.

A practical threshold: if your Magnificent Seven exposure across all accounts exceeds 25 to 30% of total equity holdings, you have moved from diversified to concentrated. The Journal of Financial Planning research cited earlier puts the drawdown risk inflection point at that same 25 to 30% single-sector concentration level.

The rebalancing decision is not binary. You do not have to exit the Mag 7. You need to know what percentage you hold and whether that percentage reflects a deliberate view or passive drift.

What Are the Tax Implications of Rebalancing Away from Concentrated Mega-Cap Tech Positions?

This is where most articles on this topic stop being useful. Let's be specific.

High-net-worth individuals with taxable income above $553,850 (married filing jointly, 2024) face the 20% long-term capital gains rate plus the 3.8% Net Investment Income Tax, per IRS Topic No. 409. That is a 23.8% combined federal rate on appreciated Magnificent Seven positions, before any state tax. In California, add another 13.3%. The friction is real.

Three mechanisms reduce that friction without requiring you to hold a concentrated position indefinitely:

Donor-Advised Fund (DAF) contribution. Donating highly appreciated Magnificent Seven shares directly to a DAF allows you to avoid capital gains tax entirely on the appreciation while receiving a fair market value deduction. If you were planning charitable giving anyway, this is tax-free portfolio rebalancing. The IRS requires the shares to have been held more than one year to qualify for the full fair market value deduction under Publication 550.

Tax-lot specific identification. If you have been buying S&P 500 index funds over multiple years, your cost basis varies significantly by lot. Selling higher-basis lots first reduces the taxable gain. Your custodian can implement specific identification if you designate it before the sale, not after.

Wash-sale rules do not apply to gains. IRC Section 1091 wash-sale rules restrict loss harvesting, not gain realization. You can sell appreciated Magnificent Seven positions and immediately reinvest in a broad ex-Mag 7 ETF or equal-weight fund without any 30-day waiting period. This removes a common behavioral barrier: many investors mistakenly believe they need to stay out of the market for 30 days after selling, when that restriction only applies to harvesting losses.

The historical S&P 500 returns data makes a relevant point here: the cost of staying concentrated in a high-multiple cohort during a valuation correction can exceed the tax cost of rebalancing. Running the math with your tax attorney before assuming the tax tail should wag the portfolio dog is worth the conversation.

How Can You Invest in the S&P 500 Excluding the Magnificent Seven?

No single ETF tracks an exact ex-Magnificent 7 construct as of 2024. Your implementation options fall into three categories.

Equal-weight index funds. The Invesco S&P 500 Equal Weight ETF (RSP) assigns each of the 500 constituents a 0.2% weight at quarterly rebalancing, per the S&P Dow Jones Indices Equal Weight Index fact sheet. This dramatically reduces Magnificent Seven concentration without eliminating those positions entirely. The Mag 7 collectively represent roughly 1.4% of RSP versus 31 to 33% of the cap-weighted index.

Sector-specific allocation. Rather than a single ex-Mag 7 vehicle, some investors build explicit overweights to financials, healthcare, and industrials using sector ETFs (XLF, XLV, XLI) while maintaining a core S&P 500 position. This approach allows more precise control over which ex-Mag 7 exposures you want and which you do not.

Factor-based funds. Value, dividend, and quality factor ETFs (VTV, VIG, QUAL) naturally underweight the Magnificent Seven relative to the cap-weighted index because those stocks screen poorly on traditional value and dividend metrics. These funds do not explicitly exclude the Mag 7, but their factor screens reduce concentration organically.

Direct indexing. For portfolios above $1M in a single account, direct indexing platforms (Parametric, Vanguard Personalized Indexing, Fidelity Managed Accounts) allow you to hold individual S&P 500 constituents and explicitly exclude or underweight specific names. This also enables continuous tax-loss harvesting at the individual security level, which is meaningfully more efficient than ETF-level harvesting for high-net-worth investors.

The implementation choice depends on account size, tax situation, and how precise you want the ex-Mag 7 tilt to be. For most FatFIRE investors, a combination of RSP plus sector overweights, layered on top of a core S&P 500 position, achieves the rebalancing objective without requiring a complete portfolio restructure.

Portfolio Construction for $5M+ Investors: Applying Ex-Mag 7 Analysis

The ex-Mag 7 framework is most useful not as a standalone allocation but as a diagnostic tool for understanding what you actually own and where your risk is concentrated.

Start with a full holdings audit across all taxable and tax-deferred accounts. Aggregate your effective exposure to each of the seven names. Include direct holdings, S&P 500 index funds (multiply the fund weight by your position size), and any tech-heavy active funds. Most investors who run this exercise for the first time find their Magnificent Seven exposure is 5 to 10 percentage points higher than they assumed.

From there, the rebalancing decision becomes a function of three variables: your concentration level relative to the 25 to 30% threshold, your tax situation in the current year, and your view on Magnificent Seven valuations relative to the ex-Mag 7 discount.

For investors in the accumulation phase, directing new contributions toward equal-weight or sector-tilted vehicles is the lowest-friction path to reducing concentration over time. No tax event, no timing decision.

For investors in the distribution phase, the higher dividend yield of the ex-Mag 7 universe (1.8 to 2.2% versus under 1.3% for the full index) creates a practical cash flow argument for rebalancing. Generating $90,000 to $110,000 in annual dividends from a $5M equity allocation versus $65,000 from the cap-weighted index is a real difference in withdrawal sustainability.

The Vanguard 2025 outlook's projection of compressed 10-year forward returns for U.S. large-cap equities, driven partly by mega-cap concentration, reinforces the case for at least examining whether your current allocation reflects a deliberate view or passive drift into a concentrated bet.

Risk Considerations: What the Ex-Mag 7 Lens Reveals

Reducing Magnificent Seven concentration does not eliminate risk. It trades one risk profile for another.

The ex-Mag 7 universe carries its own sector-specific exposures. Financials are sensitive to credit cycles and interest rate movements. A sharp recession that impairs bank earnings and widens credit spreads would hit an ex-Mag 7 overweight harder than a Magnificent Seven overweight. Energy remains volatile and correlated to geopolitical events outside any investor's control. Healthcare carries binary regulatory risk: a single drug pricing policy change can reprice an entire subsector in a day.

The correlation structure also matters. During the 2020 COVID drawdown, the Magnificent Seven recovered faster than the broader market because their businesses were structurally advantaged by remote work and digital acceleration. An ex-Mag 7 tilt would have underperformed in that specific scenario.

The honest risk assessment is this: the Magnificent Seven carry valuation and sentiment risk. The ex-Mag 7 universe carries cyclical and rate risk. Neither is obviously safer. The question is which risk you are better positioned to absorb given your time horizon, income needs, and tax situation.

What the ex-Mag 7 analysis does provide is clarity. Most investors running a standard S&P 500 index fund believe they own a diversified cross-section of American business. They own a technology-concentrated portfolio with some diversification attached. Knowing that is the starting point for every portfolio construction conversation that follows.

References

• S&P Dow Jones Indices -- "S&P 500 Equal Weight Index Fact Sheet" (2024)
• Federal Reserve Bank of San Francisco -- "Market Concentration and the Returns to Scale in U.S. Equity Markets" (2023)
• Morningstar -- "U.S. Stock Market Valuation: Price/Earnings and Related Measures" (2024)
• Vanguard -- "Vanguard Economic and Market Outlook 2025: Global Summary" (2025)
• Journal of Financial Planning -- "Concentration Risk and Portfolio Construction for High-Net-Worth Investors" (2023)
• IRS -- "Publication 550: Investment Income and Expenses" (2024)
• IRS -- "Topic No. 409: Capital Gains and Losses" (2024)
• NBER -- "The Rise of Market Power and the Macroeconomic Implications (De Loecker, Eeckhout, Unger)" (2020)